Lilly Cymbalta Halted By GMP Issues; “Approvable” Letter Issued Sept. 13

Lilly plans to keep the fill-finish production of Cymbalta (duloxetine) in Indianapolis and resolve FDA's good manufacturing practices concerns rather than pursue an alternate manufacturing arrangement for the antidepressant, Lilly said after receiving an "approvable" letter Sept. 13